Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)

被引:39
|
作者
Nier, Anika [1 ]
Huber, Yvonne [2 ]
Labenz, Christian [2 ]
Michel, Maurice [2 ]
Bergheim, Ina [1 ]
Schattenberg, Joern M. [2 ]
机构
[1] Univ Vienna, Dept Nutr Sci, Mol Nutr Sci, A-1090 Vienna, Austria
[2] Johannes Gutenberg Univ Mainz, Dept Med 1, Metab Liver Res Program, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany
关键词
non-alcoholic fatty liver disease; dietary fiber consumption; bacterial endotoxin; hepatic fibrosis; GUT MICROBIOTA; FIBROSIS; STEATOHEPATITIS; PATHOGENESIS; IMPACT; RISK;
D O I
10.3390/nu12030699
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
(1) Background: The etiology of non-alcoholic fatty liver disease (NAFLD) is multifactorial. Dietary composition has been implicated as a factor modulating intestinal barrier and could affect disease severity. The aim of this study was to evaluate dietary intake and markers of intestinal permeability in patients with NAFLD. (2) Methods: We enrolled 63 patients with NAFLD and compared them to age-matched controls. (3) Results: body mass index (BMI) and leptin to adiponectin ratio-the latter being an indicator of abdominal fat accumulation-correlated with the degree of hepatic steatosis being accompanied with rising levels of fasting insulin. Furthermore, endotoxin plasma levels and markers of inflammation were significantly higher in NAFLD compared to controls and increased with the severity of hepatic steatosis. Despite comparable intake of total energy and macronutrients, intake of fiber was lower in all patients with NAFLD compared to controls and were negatively related to disease severity. (4) Conclusions: Taken together, results of the present study suggest that fiber intake in patients is negatively related to steatosis degree and bacterial endotoxin levels, further suggesting that dietary fiber intake may be a target in NAFLD treatment (NCT: 02366052 and 03482284).
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Diagnosis of non-alcoholic fatty liver disease (NAFLD)
    Yki-Jarvinen, Hannele
    DIABETOLOGIA, 2016, 59 (06) : 1104 - 1111
  • [22] Non-alcoholic fatty liver disease (NAFLD) in children
    Roberts, EA
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 2306 - 2318
  • [23] Differential hepatic gene expression profiles between steatosis and fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)
    Lau, DTY
    Ma, HB
    Abdo, BO
    Luxon, BA
    Sinha, M
    Beard, MR
    GASTROENTEROLOGY, 2002, 122 (04) : A672 - A672
  • [24] Adipokines and cytokines in patients with non-alcoholic fatty liver disease
    Madan, Kaushal
    Prakash, Shyam
    Baba, Chalamalashetty Sreenivas
    Batra, Yogesh
    Dattagupta, Siddarth
    Panda, Subrat K.
    Acharya, Subrat K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A453 - A454
  • [25] Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease
    Abenavoli, Ludovico
    Peta, Valentina
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (03) : 134 - 140
  • [26] Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions
    Adolph, Timon E.
    Grander, Christoph
    Grabherr, Felix
    Tilg, Herbert
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [27] The significance of serum adipokines in non-alcoholic fatty liver disease
    Pulsombat, Akharawit
    Warodomwichit, Daruneewan
    Sornmayura, Pattana
    Angkathunyakul, Napat
    Rattanasiri, Sasivimol
    Chaiyaratana, Wathanee
    Kaewdoung, Pipyaporn
    Petraksa, Supanna
    Sobhonslidsuk, Abhasnee
    HEPATOLOGY, 2013, 58 : 492A - 492A
  • [28] Adipokines and cytokines in non-alcoholic fatty liver disease: Reply
    Baranova, A.
    Younossi, Z. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (02) : 267 - 268
  • [29] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Bugianesi, E
    Marzocchi, R
    Villanova, N
    Marchesini, G
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
  • [30] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    Current HIV/AIDS Reports, 2017, 14 : 47 - 53